Cobas c701 702

Manufactured by Roche

Sourced in Germany

The Cobas c701/702 is an automated clinical chemistry analyzer designed for high-volume laboratory testing. It is capable of performing a wide range of routine and specialized clinical chemistry tests, including assays for enzymes, electrolytes, proteins, and metabolites. The Cobas c701/702 is known for its high-throughput capabilities, reliability, and ease of use.

Automatically generated - may contain errors

Lab products found in correlation

Cobas e801, by Roche (3 mentions) Architect ci4100, by Abbott (2 mentions) Cobas e601, by Roche (2 mentions) Au2700, by Olympus (2 mentions) Cobas c701, by Roche (2 mentions) Gluc3, by Roche (1 mentions) Vitros 5.1 fs, by Ortho Clinical Diagnostics (1 mentions) Vacutainer vacuum system, by BD (1 mentions) Ranbut, by Randox (1 mentions) Cobas bio, by Roche (1 mentions) Nefa fa115, by Randox (1 mentions) Cobas 602, by Roche (1 mentions) Cobas 8000 analyser, by Roche (1 mentions) Proteinsimple ella, by Bio-Techne (1 mentions)

9 protocols using cobas c701 702

Quantifying Insulin Sensitivity and Lipid Profiles

Check if the same lab product or an alternative is used in the 5 most similar protocols

Sensitivity to insulin was determined applying the quantitative insulin sensitivity check index (QUICKI) [41 (link)], following the formula:
Plasma insulin (INS) [µIU/ml] concentration was assessed using electrochemiluminescence (ECLIA) with the Cobas e801 apparatus (Roche Diagnostics International Ltd., Mannheim, Germany). Glucose (GL) [mmol/l] concentration in the blood plasma was conducted by the enzymatic method with the Cobas c701/702 biochemical analyser (Roche Diagnostics International Ltd., Mannheim, Germany). The assessments were realized in conformity with the manufacturer protocol using reagents dedicated to the GLUC3 and Elecsys Insulin analysers, respectively.
The plasma levels of total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) were specified with the spectrophotometric method relying on guidelines of the clinical chemistry analyser Architect ci-4100 (Abbott Laboratories). The intra- and interassay coefficients of variation (CV) for the assays were 0.9–1.2 and 1.2–1.8%, respectively. Non-HDL cholesterol (nonHDL-C) fraction was determined following the formula:

Makiel K., Suder A., Targosz A., Maciejczyk M., Kozioł-Kozakowska A, & Haim A. (2023). Impact of Two Types of Exercise Interventions on Leptin and Omentin Concentrations and Indicators of Lipid and Carbohydrate Metabolism in Males with Metabolic Syndrome. Journal of Clinical Medicine, 12(8), 2822.

+ Open protocol

+ Expand

Biochemical Assay Methods for Clinical Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum Ca level (normal range: 8.6–10.2 mg/dL) was evaluated by the orthosolphthalein dye binding method in Cobas c 701/702 (Roche Diagnostics, Mannheim, Germany). The intra-assay and inter-assay coefficient variants for Ca were 0.9–1.2% and 1.2–1.4%, respectively. Serum PTH (normal range: 15–65 pg/mL) was evaluated by electrochemiluminescence immunoassay (ECLIA) in Cobas e-601 (Roche Diagnostics, Mannheim, Germany). The inter-assay coefficients for PTH were 1.1–2% and intra-assay coefficients for PTH were 2.8–3.4%. Plasma glucose (normal range: 74–106 mg/dL) was analyzed by the hexokinase enzymatic method (Olympus AU 2700), HbA1c (normal range: 4–6%) in TOSOH G8 (Tosoh Bioscience, San. Francisco, CA, USA). Serum total cholesterol, TG, and lipoprotein fractions were determined by colorimetric method in Cobas c 701 (Roche Diagnostics, Mannheim, Germany). LDL-C was defined by the Friedwald Formula: (total cholesterol – [HDL-C] – [TG × 0.45]) in mg/dL.

Erol R.S., Sen E.C., Ozturk F.Y., Alayci B, & Altuntas Y. (2022). Frequency of Metabolic Syndrome in Paget’s Disease of Bone. The Medical Bulletin of Sisli Etfal Hospital, 56(3), 360-364.

+ Open protocol

+ Expand

Insulin Sensitivity Assessment via HOMA-AD and HOMA-TG

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fasting plasma glucose (FPG) [mmol/L] was determined via the enzymatic method using a Cobas c701/702 biochemical analyzer (Roche Diagnostics International Ltd., Mannheim, Germany). Serum insulin concentration (INS) [µIU/mL] was determined via the electrochemiluminescence method (ECLIA) using the Cobas e801 apparatus (Roche Diagnostics International Ltd., Mannheim, Germany). The determinations were performed in accordance with the manufacturer’s instructions using reagents dedicated to the GLUC3 and Elecsys Insulin analyzers, respectively.
Using the specifications of the Architect ci-4100 clinical chemistry analyzer (Abbott Laboratories), serum triglyceride (TG) [mg/dl] levels were determined via spectrophotometry.
Evaluation of sensitivity to insulin was performed with the use of the homeostatic model assessment—adiponectin (HOMA-AD) [44 (link)] and homeostatic model assessment—triglycerides (HOMA-TG) [45 (link)], calculated based on the formula:

Makiel K., Suder A., Targosz A., Maciejczyk M, & Haim A. (2023). Exercise-Induced Alternations of Adiponectin, Interleukin-8 and Indicators of Carbohydrate Metabolism in Males with Metabolic Syndrome. Biomolecules, 13(5), 852.

+ Open protocol

+ Expand

Enzymatic Glucose and Insulin Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

The concentration of glucose in the blood plasma was performed via the enzymatic method using the Cobas c701/702 biochemical analyser (Roche Diagnostics International Ltd., Mannheim, Germany). Serum insulin concentration was determined by electrochemiluminescence (ECLIA) using the Cobas e801 apparatus (Roche Diagnostics International Ltd., Mannheim, Germany). The determinations were performed according to manufacturer guidelines with the use of reagents dedicated to the GLUC3 and Elecsys Insulin analysers, respectively. The measuring range for the glucose (GLUC3) test was 2–750 mg/dL, while for insulin (Elecsys Insulin), this totalled 0.4–1000 mU/mL. The following indices were calculated accordingly (Eqs 6, 7):

Kantorowicz M., Szymura J., Szygula Z., Kusmierczyk J., Maciejczyk M, & Wiecek M. (2021). Nordic Walking at Maximal Fat Oxidation Intensity Decreases Circulating Asprosin and Visceral Obesity in Women With Metabolic Disorders. Frontiers in Physiology, 12, 726783.

+ Open protocol

+ Expand

Fasting Blood Metabolic Profiles

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples were collected in fasting state from the antecubital vein (BD Vacutainer^® vacuum system, Franklin Lakes, NJ, USA), after approximately 8 h of sleep (last meal no more than 2 h before bedtime). The following were determined in the blood: glucose concentration (GLU), ketone bodies (KB) (β-hydroxybutyrate—BHB), triglycerides (TG) and free fatty acids (FFA). GLU concentration was determined in the plasma (EDTA and glycolysis inhibitors: sodium fluoride and potassium oxalate). Triglycerides (TG), FFA and BHB, were determined in the serum (clotting activator). The assays were carried out using commercial reagent kits according to the procedure indicated by the manufacturers.
The detection range was, respectively: 0.11–41.6 mmol/L for glucose (GLUC3 Roche Diagnostics International Ltd., Germany), 0.07–2.24 mmol/L for FFA (NEFA FA 115, Randox Laboratories Ltd., UK), 0.1–5.75 mmol/L for 3-hydroxybutyrate (Ranbut, Randox Laboratories Ltd., UK) and 0.11–5.93 mmol/L for triglycerides (TRIG, Ortho-Clinical Diagnostics, France). The determinations were performed using the Cobas c 701/702 (glucose) and Cobas Bio (FFA, BHB) analysers by Roche Diagnostics International Ltd. (Germany) and Vitros 5.1 FS (TG) by Ortho-Clinical Diagnostics (France). The intra-assay % coefficients of variation were: KB 5.2%, TG 1.1%, FFA 4.3%, GLU 1.1%.

Maciejczyk M., Bawelski M., Więcek M., Szygula Z., Michailov M.L., Vadašová B., Kačúr P, & Pałka T. (2022). Acute Effects of Whole-Body Vibration on Resting Metabolic Rate and Substrate Utilisation in Healthy Women. Biology, 11(5), 655.

+ Open protocol

+ Expand

Comprehensive Metabolic Profiling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum total Ca concentration (normal range: 8.6-10.2 mg/dL) and 24 hour urine Ca excretion (normal range:100-321 mg/24 hr) were assessed by ortho-cresolphtalein dye-binding method in Cobas c 701/702 (Roche Diagnostics, Mannheim, Germany) with the intra-and interassay coefficient variant of 0.9-1.2% and 1.2-1.4% for serum Ca; 0.8-1.4% and 1.2-1.3%,for urine Ca, respectively. Intact serum PTH (normal range:15-65 pg/mL) was measured with a electrochemiluminescence immunoassay (ECLIA) in Cobas e 601 (Roche Diagnostics, Mannheim, Germany) with the interassay and intraassay coefficient variant of 1.1-2 and 2.8-3.4%, respectively. Plasma glucose (normal range:74-106 mg/dL) was analysed using hexokinase enzymatic method (Olympus AU 2700), HbA1c (normal range:4-6%) was determined by HPLC method in TOSOH G8 (Tosoh Bioscience, San Francisco, CA, USA). Serum fasting insulin concentrations (normal range:2.6-24.9 μIU/mL) were measured by ECLIA in Cobas 602 (Roche Diagnostics, Mannheim, Germany) with the interassay and intraassay coefficient variant of 0.9-1.5% and 2.4-4.9%. Fasting total serum cholesterol, triglyceride and lipoprotein fractions were determined by calorimetric method in Cobas c 701 (Roche Diagnostics, Manheim, Germany). LDL-C was calculated with Friedewald's Formula: (total cholesterol-(HDL-C)-(triglyceride × 0.45)) in mg/dL.

Yener Ozturk F., Erol S., Canat M.M., Karatas S., Kuzu I., Dogan Cakir S, & Altuntas Y. (2016). Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocrine journal, 63(2).

+ Open protocol

+ Expand

Creatine Kinase Detection in Female Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols

The peripheral blood collected was transported immediately to the laboratory, and concentration of CK activity was detected by Roche Cobasc 701/702 using an enzymatic rate method. The laboratory reference range for this assay is 40-200 U/L for women, the central 95% of observations in caucasians [17 (link)]. Usually, the concentration of plasma creatine kinase is below 200 U/L in normal females, except for the following conditions: neuromuscular disease, strenuous physical activity, cardiovascular diseases, tumors, trauma, statins, endocrine disorders, and infectious hepatitis.

Han S., Xu H., Zheng J., Sun J., Feng X., Wang Y., Ye W., Ke Q., Ren Y., Yao S., Zhang S., Chen J., Griggs R.C., Zhao Z., Qi M, & Gatheridge M.A. (2020). Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing. BioMed Research International, 2020, 8396429.

+ Open protocol

+ Expand

Cardiometabolic Biomarkers in Preteens

Check if the same lab product or an alternative is used in the 5 most similar protocols

Non-fasting blood samples were obtained from 213 preteens. We analysed several traditional and non-traditional biomarkers that have been previously associated with adverse cardiometabolic functioning in youth [4 (link), 34 (link), 35 (link)]. Serum concentrations of glucose, insulin, total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), c-reactive protein, and C3 complement protein (C3) were all analysed on the Cobas c701/702 module of the Roche Cobas 8000 analyser (Roche Diagnostics GmbH, Penzburg, Germany). Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index was calculated using the standard formula (glucose (mmol/L) x insulin (mIU/L) / 22.5) [10 (link)]. Low density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation [36 (link)]. Serum concentrations of intracellular adhesion molecule 1 (ICAM-1), tumour necrosis factor alpha (TNF-α), growth differentiation factor-15 (GDF-15), soluble cluster of differentiation factor 163 (sCD163), leptin, interleukin-6 (IL-6), and interleukin-17A (IL-17A) were all quantified using the benchtop automated ELISA platform ProteinSimple Ella™ (Bio-Techne) following the manufacturer’s instructions. For all biomarkers, outliers more than 5 standard deviations from the mean were excluded.

Callanan S., Killeen S.L., Delahunt A., Cooney N., Cushion R., McKenna M.J., Crowley R.K., Twomey P.J., Kilbane M.T., McDonnell C.M., Phillips C.M., Cody D, & McAuliffe F.M. (2023). The impact of macrosomia on cardiometabolic health in preteens: findings from the ROLO longitudinal birth cohort study. Nutrition & Metabolism, 20, 37.

+ Open protocol

+ Expand

Cardiovascular Risk Biomarkers Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma total triglycerides (TG), Low-Density Lipoprotein cholesterol (LDLc), High-Density Lipoprotein cholesterol (HDLc), Total cholesterol (Total chol), well-known markers of cardiovascular risk, were measured using enzymatic, colorimetric assay on a Cobas c701/702 instrument (Roche Diagnostics GmbH, Mannheim, Germany). Analyzes were performed at CHU of Québec (QC, Canada).

Vodouhè M., Marois J., Guay V., Leblanc N., Weisnagel S.J., Bilodeau J.F, & Jacques H. (2022). Marginal Impact of Brown Seaweed Ascophyllum nodosum and Fucus vesiculosus Extract on Metabolic and Inflammatory Response in Overweight and Obese Prediabetic Subjects. Marine Drugs, 20(3), 174.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!